Alendronate treatment for fibrous dysplasia, a rare skeletal disorder
A Randomized, Double Blind, Placebo-Controlled Trial of Alendronate Treatment for Fibrous Dysplasia of BoneJ Clin Endocrinol Metab. 2014 Nov;99(11):4133-40.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
40 patients (24 adults and 16 children) with fibrous dysplasia (FD) were randomized to either receive alendronate administration in 6-month cycles for 24 months or placebo. The results revealed that in the alendronate group, NTX-telopeptides markers significantly declined at 18 months, however no significant difference in osteocalcin was observed between groups. Furthermore, areal bone mineral den...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE